ERBB2 and breast carcinoma: Results from the phase III SOLAR-1 study showed a 7.9-month improvement in the median overall survival of patients with advanced PIK3CA-mutated HR+/HER2– breast cancer when alpelisib was used in combination with fulvestrant, an estrogen receptor antagonist, compared to fulvestrant plus placebo15.